New antibody aims to stop bleeding episodes in rare clotting disorder
Disease control
Ongoing
This early-phase trial tests an experimental antibody called HMB-001 in 57 adults with Glanzmann thrombasthenia, a rare bleeding disorder. The study aims to see if the drug is safe and can reduce the number and severity of bleeds when given regularly. Participants receive single …
Phase: PHASE1, PHASE2 • Sponsor: Hemab ApS • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC